ClinicalTrials.Veeva

Menu

Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum (PREFER-PP)

F

Fondation Hôpital Saint-Joseph

Status

Enrolling

Conditions

Pregnancy

Treatments

Other: time trade-off technique
Other: standard-gamble technique

Study type

Interventional

Funder types

Other

Identifiers

NCT05318547
PREFER-PP

Details and patient eligibility

About

The risk of venous thromboembolism (VTE), which consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), increases during pregnancy and most strikingly in the postpartum period (6 weeks after delivery). Extensive research efforts have led to the identification of many risk factors for VTE events. Examples of such factors include maternal characteristics (personal history of VTE, thrombophilia, obesity, race) and obstetrical characteristics (methods of delivery, pre-term delivery, growth retardation). These allow care providers to risk stratify women at the time of delivery into low, moderate and high-risk women, based on experts' opinion. Further, a risk score, which was recently developed and validated on English and Swedish populations, estimates the risk of postpartum VTE in individuals.

Thromboprophylaxis (TPX) focuses on the use of short-term low-molecular-weight heparin (LMWH). LMWH is believed to reduce the risk of VTE by 50-70%, but the evidence is indirect, with a lack of large-scale randomized trial in the setting of the postpartum period. Further, LMWH is both inconvenient (subcutaneous injections) and possibly associated with haemorrhagic side effects. Alternative drugs do not exist, because direct oral anticoagulants (DOAC) and aspirin are not studied in this setting and because DOAC are contra-indicated in pregnancy and breastfeeding.

Given the unclear balance of benefits and risks, current guidelines vary greatly in the proportion of women with recommended TPX. Gassmann et al. have recently demonstrated, among a cohort of parturients at the Geneva University Hospitals: a recommendation of postpartum TPX in 40.1% of women, with an estimated mean risk of postpartum VTE of 0.12%, according to the 2015 UK guidelines (RCOG), and a recommendation of postpartum TPX in 8.7% of women, with an estimated mean risk of postpartum VTE of 0.20%, according to the 2018 US guidance (ACOG).These low risks of VTE to trigger a recommendation of TPX use contrast with that of experts' opinions, which advocate for a threshold of VTE risk of 1-3% to recommend the use of TPX. Currently, all women delivering by C-section in Geneva receive TPX regardless of their VTE risk.

This dramatic discrepancy of TPX guidance between guidelines, and between guidelines and individual experts, highlights the uncertainty in this setting. Womens' preferences would be critically important here, to guide a rationale and desired use of TPX. Quite surprisingly, such preferences have never been elicited, in spite of the very large number of births every year (5 and 4 million in Europe and the US, respectively).

To inform prescription patterns of postpartum TPX, investigators propose to conduct this prospective study to elicit values and preferences of pregnant and postpartum women.

Enrollment

52 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women aged ≥18 years
  • Ongoing pregnancy or in the early postpartum period (within 7 days of delivery)
  • Participants may be with or without prior VTE or major bleeding, and with or without previous/current use of postpartum TPX.
  • Fluency in French
  • Women are able and willing to give free, informed and written consent

Exclusion criteria

  • Fetal or neonatal death, in order not to bother women during their mourning.
  • Women under tutorship or curatorship
  • Women deprived of liberty
  • Women under court protection There will be no further exclusion criteria, to maximize the external validity of the study.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

52 participants in 2 patient groups

standard-gamble technique
Experimental group
Description:
Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants. The elicitation of health state utilites by the standard-gamble technique is further clarified.
Treatment:
Other: standard-gamble technique
time trade-off technique
Experimental group
Description:
Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
Treatment:
Other: time trade-off technique

Trial contacts and locations

1

Loading...

Central trial contact

Helene BEAUSSIER, PharmD, PhD; Justine Hugon Rodin, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems